Publications by authors named "B Dizier"

Background And Objectives: Autoantibody discovery in complex autoimmune diseases is challenging. Diverse successful antigen identification strategies are available, but, so far, have often been unsuccessful, especially in the discovery of protein antigens in which conformational and post-translational modification are critical. Our study assesses the utility of a human membrane and secreted protein microarray technology to detect autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

View Article and Find Full Text PDF
Article Synopsis
  • Bimekizumab is a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, undergoing trials for moderate-to-severe plaque psoriasis, with established maintenance dosing every 4 weeks.
  • In a study with 49 patients, 320 mg of bimekizumab was administered at specific intervals, showing significant improvement in psoriasis severity, with a peak efficacy seen around week 12.
  • Notably, the treatment not only led to clinical improvements but also normalized skin-related gene expressions, indicating a positive change in the skin's biological state, thus supporting further investigation into shorter maintenance dosing intervals.
View Article and Find Full Text PDF

Background: Platelet cytosolic cyclic adenosine monophosphate (cAMP) levels are balanced by synthesis, degradation, and efflux. Efflux can occur via multidrug resistant protein-4 (MRP4; ABCC4) present on dense granule and/or plasma membranes. As lipid rafts have been shown to interfere on cAMP homeostasis, we evaluated the relationships between the distribution and activity of MRP4 in lipid rafts and cAMP efflux.

View Article and Find Full Text PDF

Introduction: Although thioredoxin-interacting protein (TXNIP) is involved in a variety of biological functions, the contribution of endothelial TXNIP has not been well-defined in regards to endothelial and vascular function or in post-ischemic revascularisation. We postulated that inhibition of endothelial TXNIP with siRNA or in a Cre-LoxP system could be involved in protection from high fat, high protein, low carbohydrate (HFHPLC) diet-induced oxidative stress and endothelial dysfunction, leading to vascular damage and impaired revascularisation in vivo.

Methods And Results: To investigate the role of endothelial TXNIP, the TXNIP gene was deleted in endothelial cells using anti-TXNIP siRNA treatment or the Cre-LoxP system.

View Article and Find Full Text PDF

Purpose: Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non-small cell lung cancer (NSCLC) tumor samples from two phase III studies.

Experimental Design: The GS was prospectively validated using an adaptive signature design to optimize it for the sample type and technology used in phase III studies.

View Article and Find Full Text PDF